RE:RE:RE:A bunch of SHOBSI would like to pick up another 5% or so to add and that way no dilution to my position for the recent raise. But it looks like the inadequate SHOBS won't move the needle anywhere close to a decent purchase price. Glad I have the position I have accumulated.
I like to buy low. I will sell high but won't take a chance by trading this one now. Even if it was $0.50 or $1.00 or even $2.00 per share. Although once it gets over $2.00 I may cash out a modest amount.
As you know I think we reach 90 enrolled by end of 2023 and it wouldn't surprise me to see a Baxter (Vantive) offer for Spectral at that time. And the US biotech sector is surging ahead with several new IPO's leading the way right now. Very hot sector. When Vantive officially lists early in 2024 they'll be looking for some sizzle. As you say a de-risked acquisition (Spectral) would be exactly what they need. Now where are those shares at 20's or very low 30's?